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Abstract
OBJECTIVES: Long-term durability of bioprosthetic valves is predominantly limited by structural valve deterioration. RESILIA
TM
tissue has
exhibited reduced calcification in pre-clinical and early clinical studies. This study evaluated the 5-year clinical and haemodynamic out-
comes of an aortic valve with this tissue.
METHODS: This was a prospective, non-randomized, single-arm study of 133 patients implanted with a RESILIA aortic bioprosthesis be-
tween July 2011 and February 2013 at 2 sites in Poland. Clinical outcomes and haemodynamic performance were assessed annually for
5 years post-implant. Safety events were adjudicated by a Clinical Events Committee and echocardiographic data were assessed by an in-
dependent core laboratory.
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RESULTS: Mean patient age was 65.3 ± 13.5 years, with 34 patients (25.6%) <_60. The mean follow-up was 4.2 ± 1.5 years. Early (<_30 days)
and late (>30 days) all-cause mortality were 2.3% (N = 3) and 3.2%/late patients-years (N = 18) respectively. Early events included thrombo-
embolism in 3 patients (2.3%). Late valve-related events included endocarditis in 1 patient, which led to explant, and valve thrombosis in
another patient. There were no events of structural valve deterioration throughout the study. At 5 years, mean gradient was
14.8 ± 7.6 mmHg and effective orifice area was 1.4 ± 0.5 cm2, a marked improvement over baseline values. All New York Heart Association
class III patients and most class II patients at baseline had improved classifications at 5 years.
CONCLUSIONS: The bioprosthesis with RESILIA tissue demonstrated a good safety profile with excellent haemodynamic performance
over 5 years of follow-up. These encouraging outcomes warrant additional investigation of this novel tissue.
Clinical trial registration number: NCT01651052
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ABBREVIATIONS
AVR Aortic valve replacement
EOA Effective orifice area
NYHA New York Heart Association
PVL Paravalvular leak
SVD Structural valve deterioration
INTRODUCTION
Aortic valve replacement (AVR) in patients with severe aortic
stenosis relieves symptoms and increases survival [1–4]. Although
bioprosthetic valves are recommended for surgical AVR in
patients >60–65 years old, the optimal type of prosthesis in
younger patients is less clear [1–3]. The excellent durability of
mechanical valves may be offset by the need for lifetime anticoa-
gulation. Bioprosthetic valves, on the other hand, are associated
with an increased risk of structural valve deterioration (SVD), par-
ticularly in younger patients [5].
Through mid-term follow-up, contemporary bioprostheses for
AVR are not expected to deteriorate structurally, and have been
reported to exhibit freedom from either SVD or reoperation due
to SVD of between 97% and 100%. Over 5 years of follow-up, the
Carpentier-Edwards PERIMOUNTTM Magna valve series (Edwards
Lifesciences, Irvine, CA, USA) has exhibited freedom from SVD or
reoperation due to SVD of 99% [6–8]. The Trifecta bioprosthesis
(Abbott Laboratories, Santa Clara, CA, USA) over 5 years has
demonstrated similar durability, between 97% and 99% [9–12].
However, long-term durability >10 years is key, and such data
with contemporary bioprostheses are still lacking.
In an attempt to reduce SVD and improve bioprosthetic dur-
ability, a new bioprosthesis tissue platform has been developed.
RESILIATM tissue is made of bovine pericardium that undergoes
integrity preservation technology [13]. This technology consists of
stable capping that permanently blocks calcium (Ca2+) binding
sites, and glycerolization that allows dry storage of the biopros-
thesis prior to implant. The RESILIA tissue was incorporated with-
in a standard bioprosthesis design and implanted in a cohort of
133 patients who underwent surgical AVR at 2 centres in Poland.
An earlier report of this study through 1 year of follow-up found
this bioprosthesis to be safe and associated with improved
haemodynamic performance compared with baseline [14]. This
report specifies upon the final outcomes of this study over a
follow-up period of 5 years.
PATIENTS AND METHODS
Study design and patient population
This study was prospective, multicentre, single arm, and observa-
tional, designed to evaluate the safety and haemodynamic per-
formance of a novel aortic valve incorporating RESILIA tissue
(Clinical Trial Number NCT01651052). Patients who were
18 years of age or older and were candidate for AVR with or
without concomitant procedures were included. Details regard-
ing patient inclusion and exclusion criteria have been reported
previously [14]. The study protocol was reviewed and approved
by the local Ethics Committee (Jagiellonian University Bio-Ethics
Committee no. KBET/163/l/2010 of 7 October 2010) and Polish
Ministry of Health (CEBK). All study participants provided written
informed consent prior to enrolment. This report is based upon
the study’s final data extraction of 20 April 2018.
Study device and surgical procedures
The study device consisted of the model 11000 aortic biopros-
thesis (Edwards Lifesciences, Irvine, CA, USA). This tri-leaflet bio-
prosthesis is similar to the Carpentier-Edwards PERIMOUNT
Magna Ease aortic valve (Model 3300TFX, Edwards Lifesciences),
except for the RESILIA tissue leaflets. All cases were performed at
the 2 largest cardiac surgery centres in Poland. Details about the
surgical procedure have been previously reported [14]. The deci-
sion to implant the study device was based on an indication for
surgical AVR, an appropriate risk profile and a surgeon confirm-
ation that the bioprosthesis could be implanted in the consenting
patient. Per protocol, it was suggested that patients be main-
tained on oral anticoagulant therapy for 2–3 months based on
American College of Cardiology/American Heart Association
2008 guidelines [15]; however, this was left to the discretion of
the investigator.
Study end points and follow-up
Safety end points were evaluated during the early (<_30 days) and
late (>30 days) postoperative periods and were based on object-
ive performance criteria described previously [16]. All safety
events were defined according to established guidelines [17] and
were adjudicated by an independent Clinical Events Committee
and included all-cause mortality, valve-related mortality,
thromboembolism, all bleeding, major bleeding that required
transfusion, major paravalvular leak (PVL), haemolysis, valve
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dysfunction and SVD. Major PVL was defined as a PVL of any
grade resulting in intervention or considered a serious adverse
event. The definition of SVD included dysfunction or deterior-
ation involving the operated valve (exclusive of infection or
thrombosis), as determined by reoperation, autopsy or clinical
investigation [17].
Haemodynamic end points were assessed by echocardiog-
raphy and included the mean systolic transvalvular pressure gra-
dients and the effective orifice area (EOA). All echocardiography
data were analysed by an independent core laboratory
(BioTelemetry Research, Rockville, MD, USA). Patients were
assessed preoperatively, at discharge, at 3–6 months and at 1, 2,
3, 4 and 5 years of follow-up. The preoperative assessments
included valve haemodynamic performance and New York Heart
Association (NYHA) functional class. These same parameters as
well as the safety end points were assessed postoperatively, ex-
cept that haemodynamic measures were not required at the 2-
or 4-year follow-up unless murmur was heard on auscultation.
Data management and statistical analysis
The 2 investigational sites collected and recorded the clinical
data. Edwards Lifesciences, the study sponsor, monitored and
aggregated the clinical data, and analysed them per the protocol
and the statistical analysis plan. The investigators were respon-
sible for an accurate accounting of these data as represented in
this report. Summary statistics for categorical variables include
the number and percentage of subjects with a recorded value for
the variable of interest and mean ± standard deviation for con-
tinuous measures. Early safety events were defined as those
occurring <_30 days of the index procedure, and were reported as
the number of events divided by the number of enrolled sub-
jects. Linearized rates were used to summarize safety events for
the late (>30 day) postoperative period. Late event rates were cal-
culated as the number of late events divided by the total number
of late patient-years. In addition, Kaplan–Meier analyses were
undertaken on each of the safety end points and the freedom
from many of these events is reported at 5 years. SAS version 9.3
was used for all statistical analyses.
RESULTS
Baseline characteristics
A total of 133 patients requiring surgical AVR were implanted
with the study valve between July 2011 and February 2013. The
average age of the patients at implant was 65.3 ± 13.5 years, and
26% were <_60 years old. The proportion of patients with NYHA
class I, II, III and IV symptoms at baseline was 21.1%, 45.9%,
32.3% and 0.8%, respectively. Patients underwent AVR for one or
more of the following reasons: degenerative valve disease in 93
(69.9%), dystrophic calcification in 24 (18.0%), rheumatic heart
disease in 9 (6.8%), endocarditis in 2 (1.5%) and other aetiologies
in 18 (13.5%). The baseline characteristics of the patients
implanted with the study valve are summarized in Table 1.
Among key comorbidities and risk factors at baseline, 82% had
mitral insufficiency, 79% systemic hypertension, 72% aortic insuf-
ficiency, 69% hyperlipidaemia/hypercholesterolaemia, 68% tri-
cuspid insufficiency, 48% coronary artery disease, 25% cardiac
rhythm/conduction disturbance and 20% were smokers.
Procedural outcomes
All 133 patients were successfully implanted with the study valve
during the first attempt (100% technical success). Twelve patients
(9%) were implanted with a valve of 19 mm, 46 patients (35%)
with a valve of 21 mm, 41 patients (31%) with a valve of 23 mm,
24 patients (18%) with a valve of 25 mm and 10 patients (8%)
with a valve of 27 mm. Figures 1 and 2 display the surgical ap-
proach as well as aortic cross-clamp and cardiopulmonary by-
pass times. Out of 133 patients successfully implanted, 114
patients (85.7%) underwent isolated surgical AVR. The surgical
approaches consisted of a full sternotomy in 117 patients (88.0%)
and an upper mini sternotomy in 16 (12.0%). Mean aortic cross-
clamp and cardiopulmonary bypass times in all 133 patients who
underwent study device implant were 61.7 ± 14.4 and
96.2 ± 25.6 min, respectively. In the 114 patients who underwent
isolated AVR, the mean aortic cross-clamp and cardiopulmonary
bypass times were 59.6 ± 13.1 and 94.5 ± 25.2 min, respectively.
The length of hospital stay for all 133 patients was 9.7 ± 5.0 days,
with 2.2 ± 2.4 days in the intensive care unit and 7.6 ± 5.4 days in
the general ward.











Mean ± SD 61.2 ± 13.7
Range (min–max) 22.4–85.6
EuroSCORE II (%)
Mean ± SD 1.4 ± 1.0
Range (min–max) 0.5–6.0
STS risk of mortality (%)
Mean ± SD 1.4 ± 0.9
Range (min–max) 0.4–4.0
BMI (kg/m2)
Mean ± SD 29.2 ± 6.7
Range (min–max) 15.8–62.1
Underweight, n (%) 2 (1.5)
Normal weight, n (%) 31 (23.3)
Overweight, n (%) 51 (38.3)
Obese, n (%) 49 (36.8)
Aortic valve pathology, n (%)
Aortic stenosis 108 (96)
Aortic insufficiency 81 (72)
NYHA, n (%)
Class I 28 (21.1)
Class II 61 (45.9)
Class III 43 (32.3)
Class IV 1 (0.8)
Percentages are based on the total number of implanted subjects. Baseline
LVEF data were not available for 20 subjects. EuroSCORE II was not avail-
able for 20 subjects. STS risk of mortality score was not available for 23
subjects.
BMI: body mass index; EuroSCORE: European System for Cardiac Operative
Risk Evaluation; LVEF: left ventricular ejection fraction; NYHS: New York
Heart Association; SD: standard deviation; STS: Society of Thoracic
Surgeons.
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Safety outcomes
Patients were followed up for a mean of 4.2 ± 1.5 years. Early and
late safety event rates, including valve-relatedness, are summarized
in Table 2. In the early period, there were 3 all-cause deaths
(2.3%), of which 1 (0.8%) was valve-related. In the late period,
there were 18 all-cause deaths (3.2%/late patient-years), of which
4 (0.7%/late patient-years) were valve-related. Nine patients (6.8%)
and 2 patients (0.4%/late patient-years) had major bleeding in the
early and late period, respectively. There was 1 case of endocardi-
tis in the late period, which led to explant of the valve and 1 other
case of valve thrombosis which was discovered postmortem.
There were no events of SVD or of major PVL in either the early or
late period. Table 3 shows the Kaplan–Meier freedom from various
safety end points over 5 years, and Fig. 3 shows a Kaplan–Meier
curve of 2 event types: all-cause mortality and SVD.
Haemodynamic outcomes
The mean transvalvular gradients and EOAs over 5 years by valve
size are shown in Fig. 4. The gradients over 5 years represent a sus-
tained improvement compared to the values at baseline. Across all
valve sizes, the mean gradients were 13.9 ± 6.1, 13.8 ± 6.4,
14.3 ± 6.1, 15.0 ± 7.2 and 14.8 ± 7.6 mmHg at years 1–5, respective-
ly. Similarly, the overall EOAs at years 1–5 were 1.8 ± 0.6, 1.6 ± 0.5,
1.5 ± 0.5, 1.5 ± 0.4 and 1.4 ± 0.5 cm2 and represented a marked im-
provement over that observed at baseline (1.0 ± 0.8 cm2).
Transvalvular/central, paravalvular and total regurgitation are
shown in Fig. 5. The severity of transvalvular/central leak was
mild in no >5% of patients each year over the 5-year observa-
tional period, with no measurements of moderate or severe, and
with all other patients exhibiting none/trivial such leak. One pa-
tient exhibited moderate PVL at discharge, but over the annual
follow-ups, there were no observations of moderate or severe
PVL, and only a few per cent of patients exhibited even mild PVL.
New York Heart Association functional status
Ninety-one patients had their NYHA classification assessed at
baseline and 5 years (Table 4). Of the 18 class I patients at baseline,
Figure 1: Surgical approach undertaken for the study cohort.
Figure 2: Intraoperative outcomes for the study cohort. The error bars repre-
sent ± standard deviation. AVR: aortic valve replacement.
Table 2: Safety outcomes
Early (<_30 days)
events
N = 133 n, (n/N)
Early valve-related
events
N = 133 n, (n/N)
Late events (>30 days)
Late pt yrs = 554.4 n, m (m/late pt
yrs)
Late valve-related events
Late pt yrs = 554.4 n, m (m/late pt
yrs)
Mortality 3 (2.3%) 1 (0.8%) 18, 18 (3.2%) 4, 4 (0.7%)
Reoperation on study valve 0 (0%) 0 (0%) 1, 1 (0.2%) 1, 1 (0.2%)
Explant 0 (0%) 0 (0%) 1, 1 (0.2%) 1, 1 (0.2%)
Thromboembolism 3 (2.3%) 3 (2.3%) 2, 2 (0.4%) 2, 2 (0.4%)
Valve thrombosis 0 (0%) 0 (0%) 1, 1 (0.2%) 1, 1 (0.2%)
Bleeding 11 (8.3%) 0 (0%) 2, 2 (0.4%) 0, 0 (0%)
Major bleeding 9 (6.8%) 0 (0%) 2, 2 (0.4%) 0, 0 (0%)
Major paravalvular leak 0 (0%) 0 (0%) 0, 0 (0%) 0, 0 (0%)
Endocarditis 0 (0%) 0 (0%) 1, 1 (0.2%) 1, 1 (0.2%)
Haemolysis 0 (0%) 0 (0%) 0, 0 (0%) 0, 0 (0%)
Non-structural valve dysfunction 0 (0%) 0 (0%) 1, 1 (0.2%) 1, 1 (0.2%)
Structural valve deterioration 0 (0%) 0 (0%) 0, 0 (0%) 0, 0 (0%)
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72% of them remained class I after 5 years and 28% worsened. Of
the 47 class II patients at baseline, 51% improved after 5 years,
43% remained class II and 6% worsened. Of the 25 class III patients
at baseline, all of them were either class I or class II after 5 years.
The 1 class IV patient at baseline improved to class I at 5 years.
DISCUSSION
This trial evaluated the clinical outcomes and haemodynamic
performance of an aortic bioprosthesis with RESILIA tissue in 133
patients monitored over 5 years of follow-up. Valve haemo-
dynamics and safety outcomes were good. Furthermore, there
were no events of SVD over the follow-up period. A larger recent
multicentre observational study of 689 patients investigating AVR
outcomes with the same aortic valve with RESILIA tissue also
exhibited good haemodynamics and safety outcomes and zero
events of SVD through 4 years of follow-up [18, 19]. In their total-
ity, these data are encouraging for RESILIA tissue; but, of course,
longer-term data are mandatory.
Although mechanical valves are often recommended for
younger patients because they provide superior long-term dur-
ability compared to bioprostheses, patients with mechanical
valves require lifetime anticoagulation, which increases the risk of
major bleeding [2, 3]. The On-X mechanical valve, however, does
offer the advantage of requiring a lower international normalized
Table 3: Kaplan–Meier survival rates at 5 years of various safety events
Patients at risk at 5 years Cumulative events Probability event free Standard error 95% CI
Mortality 65 21 0.834 0.033 0.768–0.899
Reoperation on study valve 65 1 0.992 0.008 0.977–1.000
Explant 65 1 0.992 0.008 0.977–1.000
Thromboembolism 65 5 0.959 0.018 0.923–0.995
Valve thrombosis 65 1 0.992 0.008 0.976–1.000
All bleeding 60 13 0.898 0.027 0.845–0.951
Major bleeding 60 11 0.913 0.025 0.864–0.963
Major paravalvular leak 65 0 1.000 0.000 1.000–1.000
Endocarditis 65 1 0.992 0.008 0.977–1.000
Haemolysis 65 0 1.000 0.000 1.000–1.000
Non-structural valve dysfunction 64 1 0.991 0.009 0.974–1.000
Structural valve deterioration 65 0 1.000 0.000 1.000–1.000
CI: confidence interval.
Figure 3: Kaplan–Meier curve showing freedom from all-cause mortality and
structural valve deterioration. SE: standard error; SVD: structural valve
degeneration.
Figure 4: (A) Mean gradients in the patient cohort by valve size over the 5 year
observational period. (B) Mean effective orifice areas in the patient cohort by
valve size and over the 5 year observational period.
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ratio of 1.5–2.0, which should reduce the risk of bleeding.
Bioprosthetic valves are a reasonable option for patients who
wish to avoid long-term anticoagulation; however, these valves
are susceptible to SVD, especially in younger patients. Patient-
related risk factors for SVD include younger age, increased body
mass index, hypertension, diabetes, smoking, dyslipidaemia and
chronic renal failure; valve-related risk factors for SVD include
glutaraldehyde fixation of the leaflets, persistent left ventricular
hypertrophy, smaller prosthesis size and prosthesis–patient mis-
match [20, 21]. One of the prominent mechanisms by which SVD
occurs with tissue valves is believed to be due to calcification
over time, resulting in leaflet stiffening and/or tearing [22].
Several methods of processing leaflet tissue have been devel-
oped in order to try to reduce tissue calcification [13, 23–26]. The
RESILIA pericardial tissue undergoes an aldehyde capping pro-
cess that permanently reduces Ca2+ binding [25]. This is followed
by glycerolization to replace water, allowing dry storage. In an
elegant randomized chronic study in juvenile sheep, RESILIA tis-
sue exhibited significantly less Ca2+ content and improved
haemodynamics compared with PERIMOUNT tissue [26].
The haemodynamics of the study valve reported here over
5 years are encouraging. Mean gradients were between 10 and
15 mmHg for all valve sizes except 19 mm, which were in the 20 s
mmHg; these are qualitatively very similar to those reported over
5 years for the Carpentier-Edwards PERIMOUNT Magna valve by
Chang et al., [27] which were 11–13 mmHg. The breakdown of
haemodynamics by valve size reported here highlight the need for
consideration of aortic annular/root enlargement in AVR patients
with small annuli, especially those requiring a 19 mm valve.
Smaller valves exhibit greater increased gradients, and should
serve a reminder to all surgeons to implement as safe as possible
means to provide increased EOAs and reduced gradients [28, 29].
Smaller valves also limit the viable options that are available to
patients in the future in the event that they require reintervention.
An important finding in the present study is that the prosthe-
ses with RESILIA tissue showed no evidence of SVD over 5 years
of follow-up. Although these mid-term results are promising, it
must be recognized that SVD is infrequent in the first few years
following AVR. Based upon 12 569 patients who underwent AVR
using a Carpentier-Edwards PERIMOUNT valve, the actuarial esti-
mates of explant for SVD at 10, 15 and 20 years in patients 60–
80 years old were 1.5%, 5.1% and 8.1%, respectively [29]. In
patients <60 years old, the actuarial estimate of explant for SVD
at 10, 5 and 20 years was 5.6%, 20% and 45%, respectively.
Our observation of no SVD over 5 years compares well with
recent observations of contemporary bioprostheses. Investigating
Carpentier-Edwards PERIMOUNT Magna valves over 5 years,Figure 5: Central/transvalvular (A), paravalvular (B) and total regurgitation (C)
in the study cohort over the 5 year observational study period.
Table 4: NYHA heart failure functional class improvement from baseline to 5 years in the study cohort
Follow-up NYHA class at 5 years Class I (N = 28) Class II (N = 61) Class III (N = 43) Class IV (N = 1) Total
(N = 133)
N 18 47 25 1 91
Improved, n (%) 0 (0) 24 (51) 25 (100) 1 (100) 50 (55)
Same, n (%) 13 (72) 20 (43) 0 (0) 0 (0) 33 (36)
Worse, n (%) 5 (28) 3 (6) 0 (0) 0 (0) 8 (9)
Unknown, not done, or censored, n 10 14 18 0 42
The top row header represents patients’ NYHA class status at baseline.
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Anselmi et al. [6] and Blasco-Lucas et al. [8] reported 99.1% and
99.2% freedom from SVD, respectively; Axtell et al. [7] reported
99% freedom from reoperation due to SVD. One other contem-
porary bioprosthesis, the Trifecta valve, has demonstrated similar
durability over 5 years of follow-up. Lehmann et al. [12] and
Fukuhara et al. [10] reported 98.7% and 97.9% freedom from
SVD, respectively. Anselmi et al. [9] and Kilic et al. [11] reported
98.9% and 98.7% freedom from reoperation due to SVD.
Additionally, it should be noted that all of these published studies
report upon AVR populations with a mean age of between 70
and 75, while our cohort investigating the RESILIA tissue had a
mean age of only 65. Regardless, however, in the end, testing
with RESILIA tissue will require follow-up much beyond 5 years
in order to determine its true long-term durability [30].
Limitations
As the study was not designed with a comparator group, com-
parison of various performance measures from this study to simi-
lar measures from other studies is intrinsically compromised.
Also, because the study’s enrolment was non-consecutive, selec-
tion bias cannot be excluded. Further, a longer follow-up is
required to establish durability of this new tissue.
CONCLUSIONS
One-hundred and thirty-three patients undergoing AVR with a
RESILIA tissue valve exhibited good safety and haemodynamic
outcomes over 5 years of follow-up. Most importantly in the elu-
cidation of this tissue’s durability, zero events of SVD were
observed. Still, additional longer-term data will be necessary to
draw conclusions about the durability of this tissue compared to
that of contemporary tissue.
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